Atul Deodhar - Concepedia

Author

Atul Deodhar

Oregon Health & Science University ORCID

Also Known As

A A Deodhar, A Deodhar, A. A. DEODHAR, A. Deodhar, A.A. Deodhar, ATUL DEODHAR, Atul A Deodhar, Atul A. Deodhar, Atul Deodhar, Deodhar, A.

200

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Oregon Health & Science University Leiden University Medical Center Charité - Universitätsmedizin Berlin Rheumazentrum Ruhrgebiet Ruhr University Bochum

About

Atul Deodhar is an author at Oregon Health & Science University specializing in spondyloarthritis, rheumatology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	683
2	Orthopaedics	3	3	683
3	Rheumatology	3	3	683
4	Autoimmune Disease	1	1	349
5	Inflammation	1	1	349

Atul Deodhar

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study Désirée van der Heijde, Atul Deodhar, James Cheng‐Chung Wei, Annals of the Rheumatic Diseases	2017	361
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, The Lancet InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseSpondyloarthritis	2018	349
MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group Walter P. Maksymowych, R. Lambert, Mikkel Østergaard, Annals of the Rheumatic Diseases	2019	286
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study Jürgen Braun, Xenofon Baraliakos, Atul Deodhar, Annals of the Rheumatic Diseases	2016	260
Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study Anna Moltó, Adrien Etcheto, Désirée van der Heijde, Annals of the Rheumatic Diseases	2015	256
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study Atul Deodhar, Paula Śliwińska-Stańczyk, Huji Xu, Annals of the Rheumatic Diseases	2021	234
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen‐Week Results From a Phase <scp>III</scp> Randomized, Double‐Blind, Placebo‐Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors Atul Deodhar, Denis Poddubnyy, César Pacheco‐Tena, Arthritis & Rheumatology	2018	224
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler, The Lancet RheumatologySpondyloarthritisRheumatic DiseasesPlacebo-controlled TrialInflammatory Rheumatic Disease	2019	208
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials Stefan Schreiber, Jean‐Frédéric Colombel, Brian G. Feagan, Annals of the Rheumatic Diseases	2019	188
Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis Philip J. Mease, Atul Deodhar, Désirée van der Heijde, Annals of the Rheumatic Diseases	2022	188

Page 1